vinblastine has been researched along with er-086526 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlson, EM; Cheng, H; Du, H; Hu, Y; Jiang, Y; Lewis, BM; Littlefield, BA; Narayan, S; Seletsky, BM; Tendyke, K; Towle, MJ; Yu, MJ; Zhang, H; Zheng, W | 1 |
| Carlson, EM; Cheng, H; Condon, K; Du, H; Eckley, S; Hu, Y; Jiang, Y; Kumar, V; Lewis, BM; Littlefield, BA; Narayan, S; Saxton, P; Schuck, E; Seletsky, BM; Tendyke, K; Towle, MJ; Yu, MJ; Zhang, H; Zheng, W | 1 |
2 other study(ies) available for vinblastine and er-086526
| Article | Year |
|---|---|
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cell Line, Tumor; Furans; Humans; Ketones; Mice; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2011 |
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Drug Resistance, Neoplasm; Furans; Humans; Ketones; Mice; Mice, Inbred BALB C; Xenograft Model Antitumor Assays | 2011 |